Loading…
ImmunityBio, Inc. is projected to rise to $9.81 by 2027, a +24% move from its current price of $7.89. IBRX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $7.55 | $7.89 | $8.25 | +0.03% |
| May 30 | $7.41 | $7.89 | $8.41 | +0.06% |
| May 31 | $7.31 | $7.90 | $8.53 | +0.09% |
| Jun 1 | $7.23 | $7.90 | $8.63 | +0.12% |
| Jun 2 | $7.16 | $7.90 | $8.73 | +0.15% |
| Jun 3 | $7.09 | $7.90 | $8.81 | +0.18% |
| Jun 4 | $7.03 | $7.91 | $8.89 | +0.21% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.03 | $7.91 | $8.89 | +0.21% |
| Week 2 | $6.71 | $7.92 | $9.35 | +0.42% |
| Week 3 | $6.48 | $7.94 | $9.73 | +0.63% |
| Week 4 | $6.29 | $7.96 | $10.06 | +0.84% |
| Week 5 | $6.13 | $7.97 | $10.36 | +1.05% |
| Week 6 | $5.99 | $7.99 | $10.65 | +1.26% |
| Week 7 | $5.87 | $8.01 | $10.92 | +1.47% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology.
ImmunityBio is based in San Diego, California. It has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute.
ImmunityBio, Inc. (IBRX) is a biotechnology company in the Healthcare sector. The current price is $7.89 per share, and the market cap is $8.26B. The company is ranked 1025 in market capitalization.
The near-term picture shows a current price around the referenced level, with a defined 30-day range and a steady technical backdrop. The forecast for 2026 lists an average price of $7.89, with a min of $2.02 and a max of $10.91, and a 0% ROI, reflecting a neutral near-term stance. Longer-term forecasts point to meaningful upside over the coming years, culminating in significantly higher averages by 2030 and beyond.
Looking further out, the projected path moves from an average of $9.81 in 2027 toward higher annual averages (e.g., $19.53 by 2030 and $116.79 by 2050), with corresponding gains in ROI that rise from 24.4% in 2027 to 1,380.2% by 2050. Current positioning and the multi-year outlook suggest potential upside, balanced against the inherent uncertainty of long-range market forecasts.
A major floor 30.0% below — a decisive break under it would weaken the trend.
The nearest floor, 11.8% below — buyers have tended to step in here.
The nearest ceiling, 7.9% above — a clean break opens room to run.
A major ceiling 46.4% above — clearing it would confirm fresh momentum.
Key IBRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IBRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.76 | Buy | $7.80 | Buy |
| MA 10 | $7.88 | Buy | $7.83 | Buy |
| MA 20 | $7.80 | Buy | $7.81 | Buy |
| MA 50 | $7.72 | Buy | $7.63 | Buy |
| MA 100 | $7.15 | Buy | $6.87 | Buy |
| MA 200 | $4.75 | Buy | $5.65 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.24 | Neutral |
| Stoch RSI (14) | 53.14 | Neutral |
| CCI (20) | 18.00 | Neutral |
| Williams %R (14) | -48.06 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -7.29 | Sell |
| Bollinger %B (20,2) | 0.56 | Neutral |
| Stochastic %K (14) | 51.94 | Neutral |
| TRIX (15) | 0.12 | Buy |
| Awesome (5,34) | 0.04 | Buy |
| Ultimate (7,14,28) | 47.79 | Neutral |
| Momentum (10) | -0.23 | Sell |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 7.61 | Buy |
| ADX (14) | 7.49 | Neutral |
| ATR (14) | 0.30 | Info |
The near-term technical picture is described as BULLISH. The RSI(14) sits at 50, with the 50-day moving average at $7.72 and the 200-day moving average at $4.75, reinforcing a constructive setup. Support is noted at $6.96 and resistance at $8.51, defining a concrete trading range.
Over the last 30 days, the stock traded between $5.89 and $10.57, highlighting ample nearby levels for potential entry or exit.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.02 | $7.89 | $10.91 | 0% | Neutral | |
| $7.31 | $9.81 | $14.18 | +24% | Bullish | |
| $9.59 | $13.49 | $20.56 | +71% | Bullish | |
| $12.06 | $17.68 | $28.08 | +124% | Bullish | |
| $12.85 | $19.53 | $32.12 | +148% | Bullish | |
| $12.55 | $19.73 | $33.43 | +150% | Bullish | |
| $13.51 | $21.93 | $38.16 | +178% | Bullish | |
| $13.71 | $22.94 | $40.91 | +191% | Bullish | |
| $15.83 | $27.29 | $49.74 | +246% | Bullish | |
| $20.32 | $36.04 | $67.03 | +357% | Bullish | |
| $23.71 | $48.17 | $97.47 | +511% | Bullish | |
| $52.55 | $116.79 | $266.37 | +13.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.02 | $7.89 | $9.28 | +0.00% |
| June 2026 | $6.45 | $7.67 | $9.43 | -2.73% |
| July 2026 | $6.72 | $8.11 | $10.18 | +5.64% |
| August 2026 | $6.83 | $8.34 | $10.64 | +2.87% |
| September 2026 | $6.55 | $8.07 | $10.43 | -3.22% |
| October 2026 | $6.55 | $8.14 | $10.65 | +0.83% |
| November 2026 | $6.76 | $8.46 | $11.18 | +3.94% |
| December 2026 | $6.49 | $8.17 | $10.91 | -3.40% |
Click any year to see its month-by-month IBRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect IBRX to range from $2.02 to $10.91 through 2026. The $7.89 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The IBRX price prediction for 2027 points to an average of $9.81 (low $7.31, high $14.18) — a potential gain of +24% on today's $7.89. Buyers look set to stay in control over this stretch.
In 2028, IBRX is projected to trade between $9.59 and $20.56, averaging $13.49 — a potential gain of +71% from today's $7.89. That is up +37% on the projected 2027 average. Momentum favours further upside here.
ImmunityBio, Inc.'s 2029 outlook centres on $17.68, within a $12.06 to $28.08 range. That is up +31% on the projected 2028 average. That marks a +124% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, IBRX could reach as high as $32.12, with a base case around $19.53 and support toward $12.85 — roughly +148% from $7.89. Momentum favours further upside here.
Expect IBRX to range from $12.55 to $33.43 through 2031. The $19.73 average target implies a +150% move from current prices. That is up +1% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The IBRX price prediction for 2032 points to an average of $21.93 (low $13.51, high $38.16) — a potential gain of +178% on today's $7.89. Momentum favours further upside here.
In 2033, IBRX is projected to trade between $13.71 and $40.91, averaging $22.94 — a potential gain of +191% from today's $7.89. That is up +5% on the projected 2032 average. Buyers look set to stay in control over this stretch.
ImmunityBio, Inc.'s 2034 outlook centres on $27.29, within a $15.83 to $49.74 range. That is up +19% on the projected 2033 average. That marks a +246% change versus current levels. Momentum favours further upside here.
By 2035, IBRX could reach as high as $67.03, with a base case around $36.04 and support toward $20.32 — roughly +357% from $7.89. Buyers look set to stay in control over this stretch.
Expect IBRX to range from $23.71 to $97.47 through 2040. The $48.17 average target implies a +511% move from current prices. That is up +34% on the projected 2035 average. Momentum favours further upside here.
The IBRX price prediction for 2050 points to an average of $116.79 (low $52.55, high $266.37) — a potential gain of +13.8x on today's $7.89. Buyers look set to stay in control over this stretch.
Investing $1,000 in IBRX today (≈ 126.742712 IBRX) could be worth
$14,801.84
+$13,801.84 (+1380%) by 2050 · US Dollar
Based on the average projected IBRX price of $116.79 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IBRXwould be worth at today's price.
$1,000 invested in IBRX on May 27, 2025 (≈ 395.256921 IBRX) would be worth
$3,118.58
+$2,118.58 (+211.9%) today · 3.12× · US Dollar
Based on a IBRX entry price of $2.53 vs. today's $7.89.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.05 | $980.12 | -2.0% |
| 1 month ago | $7.29 | $1,082.3 | +8.2% |
| 3 months ago | $9.55 | $826.18 | -17.4% |
| 6 months ago | $2.36 | $3,343.22 | +234.3% |
| 1 year ago | $2.53 | $3,118.58 | +211.9% |
| All time (5.0y) ago | $17.59 | $448.55 | -55.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IBRX forecast.
Our base-case forecast reaches $16.00 around 2029.
Implied market cap at $16.00: $16.76B
The multi-year forecast shows a clear upside trajectory after 2026. For 2027 the average price is projected at $9.81 with a 24.4% ROI and bullish sentiment. 2028 carries an average of $13.49 and a 71% ROI, with continued bullish momentum.
In 2029 the average is $17.68 and ROI reaches 124.1%. By 2030, the average price is $19.53 with a 147.5% ROI, and by 2031 the average is $19.73 with a 150.1% ROI. 2032's avg reaches $21.93 (177.9% ROI), 2033 at $22.94 (190.8%), and 2034 at $27.29 (245.9%).
The 2035 forecast shows an average of $36.04 with a 356.8% ROI. The path extends to 2040 with an average of $48.17 and a 510.5% ROI, and to 2050 with an average of $116.79 and a 1380.2% ROI. Across these years the sentiment remains BULLISH, reflecting an expectation of sustained upside from the current levels, albeit with inherent uncertainty in any long-range projection.
Tap a question to reveal the answer.
The 2030 forecast lists an average price of $19.53 with a 147.5% ROI and a max of $32.12.
Forecasts show bullish sentiment from 2027 onward, with average prices rising and ROIs reaching 24.4% in 2027 and up to 150.1% by 2031, culminating in a 1380.2% ROI by 2050, though these are estimates and not guarantees.
In 2040 the max forecast is $97.47, which is below $100, while 2050’s max is $266.37.
Current price is $7.89 and market cap is $8.26B.
The 30-day range is $5.89 to $10.57.
ImmunityBio, Inc. Community Discussion
0Share your ImmunityBio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.